This Article Full Text Full Text (PDF) Supplemental Data Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cosma, M. Articles by Montori, V. M. Search for Related Content PubMed PubMed Citation Articles by Cosma, M. Articles by Montori, V. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB METFORMIN HYDROCHLORIDE Related Collections Female Endocrinology

Insulin Sensitizers for the Treatment of Hirsutism: A Systematic Review and Metaanalyses of Randomized Controlled Trials

Knowledge and Encounter Research Unit (M.C., B.A.S., D.N.F., D.M.K., M.L.L., R.J.M., M.B.E., P.J.E., V.M.M.) and Division of Endocrinology, Diabetes, Metabolism, and Nutrition (M.C., B.A.S., V.M.M.), Department of Medicine, and Mayo Clinic Libraries (P.J.E.), Mayo Clinic College of Medicine, Rochester, Minnesota 55905; and State University of New York at Geneseo (M.L.L.), Geneseo, New York 14454

Address all correspondence and requests for reprints to: Victor M. Montori, M.D., M.Sc., Mayo Clinic, W18A, 200 First Street SW, Rochester, Minnesota 55905. E-mail: montori.victor{at}mayo.edu.

Context: Insulin sensitizers, including metformin and thiazolidinediones (TZDs), improve hyperinsulinemia and reproductive dysfunctions in some women with hyperandrogenism. The extent to which these agents improve hirsutism remains unclear.

Objective: Our objective was to conduct a systematic review and metaanalyses of randomized controlled trials of metformin or TZDs for the treatment of hirsutism.

Data Sources: We searched the following databases: MEDLINE, EMBASE, and Cochrane CENTRAL (up to May 2006). Review of reference lists and contact with hirsutism experts further identified candidate trials.

Study Selection: Reviewers working independently and in duplicate, with acceptable chance-adjusted agreement ( = 0.72), determined trial eligibility. Eligible trials randomly assigned women with hirsutism to at least 6 months of insulin sensitizers or control and measured hirsutism outcomes.

Data Extraction: Reviewers working independently and in duplicate determined the methodological quality of trials and collected data on patient characteristics, interventions, and outcomes.

Data Synthesis: Of 348 candidate studies, 16 trials (22 comparisons) were eligible. The methodological quality of these trials was low. Random-effects metaanalyses showed a small decrease in Ferriman-Gallwey scores in women treated with insulin sensitizers compared with placebo [pooled weighted mean difference (WMD) of –1.5; 95% confidence interval (CI), –2.8 to –0.2; inconsistency (I²) = 75%]. There was no significant difference between insulin sensitizers and oral contraceptives (WMD of –0.5; CI, –5.0, 3.9; I² = 79%). Metformin was inferior to both spironolactone (WMD of 1.3; CI, 0.03, 2.6) and flutamide (WMD of 5.0; CI, 3.0, 7.0; I² = 0%).

Conclusions: Imprecise and inconsistent evidence of low to very low quality suggests that insulin sensitizers provide limited or no important benefit for women with hirsutism.

This article has been cited by other articles:

				O. Koulouri and G. S Conway Management of hirsutism BMJ, March 27, 2009; 338(mar27_1): b847 - b847. [Full Text]

				S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr. Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review Endocr. Rev., February 1, 2009; 30(1): 1 - 50. [Abstract] [Full Text] [PDF]